Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four virtual investor conferences throughout September 2021. Key events include the Barrington Research 14th Annual Virtual Fall Investment Conference and Morgan Stanley's 19th Annual Global Healthcare Conference, both on September 9. Additionally, LeMaitre will participate in Lake Street's 5th Annual Best Ideas Growth Conference on September 14 and the 2021 Cantor Virtual Global Healthcare Conference on September 27, where David Roberts, President, will present at 8:00 AM ET.
LeMaitre specializes in devices and services for peripheral vascular disease, impacting over 200 million globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in August 2021. CFO JJ Pellegrino will present at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 9:00 AM EDT and will also attend the Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16. LeMaitre specializes in devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.
LeMaitre (Nasdaq:LMAT) reported Q2 2021 results with sales of $40.7 million, a 64% increase year-over-year. Operating income rose by 128% to $11.1 million, yielding an operating margin of 27%. Net income jumped 137% to $8.3 million, with earnings per diluted share at $0.40, a 131% increase. Despite a gross margin decline to 65.8%, driven by product mix and manufacturing inefficiencies, the company completed a $54.5 million follow-on stock offering. Q3 2021 guidance suggests sales between $38.3 million and $40.3 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q2 2021 financial results on July 29, 2021, after market close. A conference call is set for the same day at 5:00 PM ET to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 or through a webcast at the company’s investor relations page. LeMaitre specializes in devices for peripheral vascular disease, serving over 200 million worldwide.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) has priced a public offering of 1,000,000 shares at $54.50 each, expecting gross proceeds of approximately $54.5 million. Closing is anticipated around July 16, 2021. Underwriters have an option to buy 150,000 additional shares. Proceeds will be used to repay senior secured credit facility borrowings, for corporate purposes, and potential acquisitions. The offering follows SEC registration and is conducted via a prospectus. Jefferies and Stifel are the joint book-running managers for this offering.
LeMaitre Vascular (Nasdaq:LMAT) has begun an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The proceeds will be used to fully repay borrowings under its senior secured credit facility and for corporate purposes, including working capital and potential acquisitions. Jefferies LLC and Stifel are the joint book-running managers. The offering is subject to market conditions, and details will be available in the SEC filings.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced preliminary Q2 2021 results, reporting net sales of $40.7 million, a 64% increase compared to Q2 2020, with organic growth of 35%. Operating income reached approximately $10.9 million to $11.3 million, up 128%. The gross margin declined to 65.5%-66.1%, impacted by inventory write-downs and manufacturing inefficiencies. Geographic sales growth was strong across all regions, especially in the Americas (+83%). Cash and cash equivalents stood at $21.8 million, while debt decreased by $9 million to $23 million.
LeMaitre Vascular (Nasdaq:LMAT) announced that President David Roberts will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on June 10, 2021, at 5:30 PM ET. The company specializes in devices, implants, and services for peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices tailored to vascular surgeons.
LeMaitre (Nasdaq:LMAT) announced the receipt of CE marks for five vascular products after a prior lapse due to a change in notified bodies. The newly certified products include XenoSure Biologic Patches, AlboGraft Polyester Vascular Grafts, and various Carotid Shunts, with expiration dates extending to 2024. Notably, the XenoSure's indications no longer cover neuro or cardiac applications. Andrew Hodgkinson highlighted that despite some product line losses totaling 3% of EMEA sales, customer supplies remained largely uninterrupted due to existing inventory.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will have its CFO, JJ Pellegrino, present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 1:30 PM EDT. The company specializes in devices and services for peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices aimed at vascular surgeons. For more details, visit www.lemaitre.com.